Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:3.1.1.53 (
sialidase
)
2,694
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
We explored the genetic basis for intraspecific variation in mycoplasmal
sialidase
activity that correlates with virulence, and its potentially advantageous linkage to nutrient catabolism. Polymorphism in N-acetylneuraminate scavenging and degradation genes (
sialidase
,
N-acetylneuraminate lyase
, N-acetylmannosamine kinase, N-acetylmannosamine-6-phosphate epimerase, N-acetylglucosamine-6-phosphate deacetylase, and glucosamine-6-phosphate deaminase) was evident among eight strains of the avian pathogen Mycoplasma synoviae. Most differences were single nucleotide polymorphisms, ranging from 0.34+/-0.04 substitutions per 100 bp for N-acetylmannosamine kinase to 0.65+/-0.03 for the single-copy
sialidase
gene nanI. Missense mutations were twice as common as silent mutations in nanI; 26% resulted in amino acids dissimilar to consensus; and there was a 12-base deletion near the nanI promoter in strain WVU1853(T), supporting a complex genetic basis for differences in
sialidase
activity. Two strains had identical frameshifts in the
N-acetylneuraminate lyase
gene nanA, resulting in nonsense mutations, and both had downstream deletions in nanA. Such genetic lesions uncouple extracellular liberation of sialic acid from generation of fructose-6-phosphate and pyruvate via intracellular N-acetylneuraminate degradation. Retention of nanI by such strains, but not others in the M. synoviae phylogenetic cluster, is evidence that
sialidase
has an important non-nutritional role in the ecology of M. synoviae and certain other mycoplasmas.
...
PMID:Genetic variation in sialidase and linkage to N-acetylneuraminate catabolism in Mycoplasma synoviae. 1849 Jan 31
<< Previous
1
2